Cargando…
Nivolumab for Metastatic Cutaneous Squamous Cell Carcinoma
Nivolumab is a programmed death receptor 1 (PD-1) inhibitor. It is part of a group of drugs known as immune checkpoint blockers, which enable potent and durable T-cell responses against several tumors. We report the case of a patient with a metastatic squamous cell carcinoma, who is being treated wi...
Autores principales: | Oro-Ayude, Marcos, Suh-Oh, Hae Jin, Sacristán-Santos, Victor, Vázquez-Bartolomé, Patricia, Flórez, Ángeles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315375/ https://www.ncbi.nlm.nih.gov/pubmed/32595466 http://dx.doi.org/10.1159/000505478 |
Ejemplares similares
-
Secondary Adrenal Insufficiency in a Patient with Metastatic Melanoma Treated with Nivolumab
por: Omata, Wataru, et al.
Publicado: (2022) -
Acanthosis Nigricans and Hypochondroplasia Associated with FGFR3 Mutation: A Case Report
por: Soto-García, Diego, et al.
Publicado: (2023) -
Unusual Presentation of Cutaneous Spindle Cell Squamous Cell Carcinoma: A Case Report
por: Wernheden, Erika, et al.
Publicado: (2020) -
Use of Talimogene Laherparepvec to Treat Cutaneous Squamous Cell Carcinoma in a Renal Transplant Patient
por: Miller, Max, et al.
Publicado: (2023) -
Nivolumab-Induced de novo Discoid Lupus Erythematosus
por: Manjunath, Jaya, et al.
Publicado: (2022)